PRMT5 and its accompanying methyltransferase activity has been implicated in cancer tumorigenesis and as a marker of poor prognosis, suggesting an oncogenic role in many human cancers and making it an attractive therapeutic target for drug development [77;79]. The gene discussed is PRMT5; the disease is cancer.